Korsana Biosciences (KRSA) Stock Overview

Develops therapeutic antibodies for the treatment of neurodegenerative diseases. More details

KRSA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings are forecast to decline by an average of 29.4% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

KRSA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW430,784 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

430,784 investors already sharing narratives

View all narratives

Korsana Biosciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Korsana Biosciences
Historical stock prices
Current Share Price	US$34.99
52 Week High	US$59.36
52 Week Low	US$7.19
Beta	1.75
1 Month Change	28.50%
3 Month Change	52.86%
1 Year Change	64.43%
3 Year Change	35.10%
5 Year Change	-92.73%
Change since IPO	-98.00%

Recent updates

Shareholder Returns

	KRSA	US Biotechs	US Market
7D	10.7%	0.3%	-0.1%
1Y	64.4%	36.3%	11.9%

Return vs Industry: KRSA exceeded the US Biotechs industry which returned 36.3% over the past year.

Return vs Market: KRSA exceeded the US Market which returned 11.9% over the past year.

Price Volatility

Is KRSA's price volatile compared to industry and market?
KRSA volatility
KRSA Average Weekly Movement	14.5%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.8%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	2.9%

Stable Share Price: KRSA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: KRSA's weekly volatility has decreased from 46% to 14% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2024	19	Jonathan Violin	korsana.com

Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders.

Korsana Biosciences, Inc. Fundamentals Summary

How do Korsana Biosciences's earnings and revenue compare to its market cap?
KRSA fundamental statistics
Market cap	US$1.59b
Earnings (TTM)	-US$49.08m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-32.5x

P/E Ratio

Is KRSA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KRSA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$49.08m
Earnings	-US$49.08m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-1.08
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did KRSA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/21 07:47
End of Day Share Price	2026/09/18 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Korsana Biosciences, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Paul Matteis	Stifel, Equities Research
Tyler Van Buren	TD Cowen
David Bautz	Zacks Small-Cap Research

Korsana Biosciences, Inc.NasdaqCM:KRSA Stock Report